Non-Hodgkin Lymphoma

Bruton tyrosine kinase (BTK) inhibitors play an important role in the therapeutic spectrum of B-cell lymphomas.

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD, discusses the data from the SADAL trial that led to the FDA approval of selinexor for use in patients with diffuse large B-cell lymphoma.

Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.

Connie L. Batlevi, MD, PhD, discusses challenges faced in the treatment of patients with follicular lymphoma.

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.

Kami J. Maddocks, MD, discusses unanswered questions with BTK inhibitors in B-cell malignancies.

John M. Burke, MD, discusses treatment options for patients with early-stage or advanced follicular lymphoma with a low tumor burden.

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.

Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.

The European Commission has approved an expanded indication of ibrutinib for use in combination with rituximab in treatment-naïve adult patients with chronic lymphocytic leukemia.

Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.

Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.

A supplemental biologics license application has been filed with the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma following 2 or more previous lines of systemic therapy.